Suzhou Puhe Biopharma Co. Ltd. has disclosed histone deacetylase 1 (HDAC1) inhibitors acting as REST Corepressor 1 (RCOR1; CoREST)/histone deacetylase (HDAC) complex inhibitors reported to be useful for the treatment of cancer.
A Suzhou Puhe Biopharma Co. Ltd. patent reports new Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors described as potentially useful for the treatment of cancer.
Suzhou Puhe Biopharma Co. Ltd. has divulged protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Suzhou Puhe Biopharma Co. Ltd. researchers have prepared and tested substituted bicyclic heteroaryl compounds acting as GTPase KRAS (G12D mutant) inhibitors potentially useful for the treatment of cancer.
Suzhou Puhe Biopharma Co. Ltd. presented promising preclinical profile data on PH009-1, a novel fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Besides ex19del (D), L858R (L) and T790M (T) as the more prevalent EGFR mutations, a segment of patients further acquire C797S (C)-resistant mutation. Current therapies address some single, double or triple mutation-expressing cancers. However, multiple-mutant positive cancers where T790M and/or C797S are involved pose a treatment challenge. The development of pan mutant EGFR TKIs is thus a much-desired research goal.
